Rozlytrek Union européenne - slovaque - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastické činidlá - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Erlotinib Teva 150 mg filmom obalené tablety Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

erlotinib teva 150 mg filmom obalené tablety

teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica

Erlotinib Teva 100 mg filmom obalené tablety Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

erlotinib teva 100 mg filmom obalené tablety

teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica